| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/16/2006 | US20060034870 Increasing the immunogenicity of an antigen or a hapten by attaching it to an adjuvant having a fragment with a specific amino acid sequence of the P40 protein of Klebsiella pneumoniae to form an immunogenic complex |
| 02/16/2006 | US20060034869 Drug for treating liver diseases with the use of hollow protein nanoparticles |
| 02/16/2006 | US20060034868 Veterinary medicine; respiratory system disorders; inoculating with attenuation virus |
| 02/16/2006 | US20060034867 Administering a vaccine comprising recombinant avipox vector containing and expressing an exogeneous nucleotide sequence encoding FeLV immunogen and an acceptable vehicle or diluent, to a felidae with a liquid jet needle-free injector, wherein the vaccine comprises 104.5-107.0 TCID50/dose |
| 02/16/2006 | US20060034866 Adipocyte complement related protein homolog zacrp3 |
| 02/16/2006 | US20060034865 Soluble MHC artificial antigen presenting cells |
| 02/16/2006 | US20060034864 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 02/16/2006 | US20060034863 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 02/16/2006 | US20060034862 Method for diagnosing early and late lyme borreliosis |
| 02/16/2006 | US20060034861 HCV E1 comprising specific disulfide bridges |
| 02/16/2006 | US20060034860 Protein-protein interactions in human immunodeficiency virus |
| 02/16/2006 | US20060034859 Naturally processed measles virus peptides eluted from class II HLA molecules |
| 02/16/2006 | US20060034858 A beta or an immunogenic fragment thereof presented by a virus or bacteria as part of an immunogenic composition effective to induce an immunogenic response comprising antibodies against A beta |
| 02/16/2006 | US20060034857 Administering an isolated polynucleotide encoding a Notch ligand comprising a Delta Serrate Ligand (DSL) domain to a cell of a patient; the Notch ligand is expressed and interacts with a Notch receptor to reduce T-cell activation; antiallergens; graft rejection; autoimmune disease |
| 02/16/2006 | US20060034856 Epha2 antigen t epitopes |
| 02/16/2006 | US20060034855 Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein |
| 02/16/2006 | US20060034854 Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
| 02/16/2006 | US20060034853 Novel human virus causing respiratory tract infection and uses thereof |
| 02/16/2006 | US20060034852 Comprising transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety and an immunoglobulin moiety comprising a heavy chain constant region of an immunoglobulin; interfere with binding of a tumor necrosis factor receptor with its ligand; antitumor agents |
| 02/16/2006 | US20060034851 Targeted therapeutic delivery of vitamin D compounds |
| 02/16/2006 | US20060034850 Antibodies as T cell receptor mimics, methods of production and uses thereof |
| 02/16/2006 | US20060034849 Antibodies reactive with beta (1-3)-glucans |
| 02/16/2006 | US20060034848 Methods and compositions for treating Alzheimer's disease |
| 02/16/2006 | US20060034847 Methods of treating a subject for a condition |
| 02/16/2006 | US20060034846 Use of TF antagonists |
| 02/16/2006 | US20060034845 Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| 02/16/2006 | US20060034844 Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| 02/16/2006 | US20060034843 Interaction of Smad6 with Hox proteins and uses thereof |
| 02/16/2006 | US20060034842 Treating ErbB2-expressing breast cancer in a human by administering huMAb4D5-8 antibody and humanized 2C4 antibody variant 574 |
| 02/16/2006 | US20060034841 Method of depleting regulatory T cell |
| 02/16/2006 | US20060034840 ErbB antagonists for pain therapy |
| 02/16/2006 | US20060034839 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 02/16/2006 | US20060034838 Anti-human VEGF receptor Flt-1 monoclonal antibody |
| 02/16/2006 | US20060034837 Method and agents for the prevention, inhibition and therapy of cancers |
| 02/16/2006 | US20060034836 administering immunoglobulins linked to proteins having amino acid replacements in the amino acid sequence, to increase the circulating half-life in vivo than a corresponding antibody-based fusion proteins without amino acid replacements; reducing tumor size and metastasis in mammals |
| 02/16/2006 | US20060034835 Immunoglobulin variants and uses thereof |
| 02/16/2006 | US20060034834 Intrabody-mediated control of immune reactions |
| 02/16/2006 | US20060034833 Single domain antibodies directed against interferron-gamma and uses therefor |
| 02/16/2006 | US20060034832 Cell death inhibitor |
| 02/16/2006 | US20060034831 Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| 02/16/2006 | US20060034830 Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
| 02/16/2006 | US20060034829 Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
| 02/16/2006 | US20060034828 glycoproteins; glycans; increased antibody-dependent cellular cytotoxicity (ADCC) activity; kits |
| 02/16/2006 | US20060034827 Stabilized liquid anti-rsv antibody formulations |
| 02/16/2006 | US20060034826 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 02/16/2006 | US20060034812 Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
| 02/16/2006 | US20060034811 Melanoma vaccine and methods of making and using same |
| 02/16/2006 | US20060034810 Novel artificial antigen presenting cells and uses therefor |
| 02/16/2006 | US20060034767 Targeting and tracking of cells to specific organs and tissues in vivo |
| 02/16/2006 | US20060034764 Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 02/16/2006 | DE102004036881A1 Bioresorbierbares Material zur Füllung von Knochendefekten Bioresorbable material for filling bone defects |
| 02/16/2006 | CA2577270A1 Antibiotic resistance free dna vaccines |
| 02/16/2006 | CA2576627A1 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| 02/16/2006 | CA2576405A1 Antibody and utilization of the same |
| 02/16/2006 | CA2576193A1 Taj in neuronal function |
| 02/16/2006 | CA2575994A1 Optimizing expression of active botulinum toxin type a |
| 02/16/2006 | CA2575541A1 New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| 02/16/2006 | CA2575293A1 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus |
| 02/16/2006 | CA2573631A1 Recombinant rabies virus compositions |
| 02/16/2006 | CA2573293A1 Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby |
| 02/16/2006 | CA2572326A1 Capsules containing transfected cells, method for preparing the same and uses thereof for immunization and vaccination |
| 02/15/2006 | EP1626096A2 In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/15/2006 | EP1626091A2 Duplexed parvovirus vectors |
| 02/15/2006 | EP1626084A1 Compositions and methods for the diagnosis of tumours |
| 02/15/2006 | EP1626059A1 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| 02/15/2006 | EP1626058A1 Compositions and methods for the diagnosis of tumour |
| 02/15/2006 | EP1625852A1 Chimeric flavivirus vaccines |
| 02/15/2006 | EP1625218A2 Heparanase-derived peptides for vaccination of tumor patients |
| 02/15/2006 | EP1625214A1 New enterovirus, vaccines, medicaments and diagnostic kits |
| 02/15/2006 | EP1625209A2 Immunoglobulin chimeric monomer-dimer hybrids |
| 02/15/2006 | EP1625205A2 Ancestral viruses and vaccines |
| 02/15/2006 | EP1625167A1 Hypoallergenic variants of the parietaria judaica major allergens, uses thereof and compositions comprising them |
| 02/15/2006 | EP1625166A1 Antibodies to masp-2 |
| 02/15/2006 | EP1625164A1 Method of detecting probnp with a monoclonal antibody binding to the amino acids 41-46 |
| 02/15/2006 | EP1625163A1 Method of detecting probnp with a monoclonal antibody binding to the amino acids 38-44 |
| 02/15/2006 | EP1625157A2 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation |
| 02/15/2006 | EP1625151A2 Comparative ligand mapping from mhc class i positive cells |
| 02/15/2006 | EP1625144A2 Polyvalent immunogen |
| 02/15/2006 | EP1625141A2 Grp94-based compositions and methods of use thereof |
| 02/15/2006 | EP1625140A2 Branched immunomodulatory compounds and methods of using the same |
| 02/15/2006 | EP1624892A2 Therapeutic use of anti-cs1 antibodies |
| 02/15/2006 | EP1624891A2 Clotting factor-fc chimeric proteins to treat hemophilia |
| 02/15/2006 | EP1624890A2 Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes |
| 02/15/2006 | EP1624889A2 Compositions for inducing immune responses |
| 02/15/2006 | EP1624888A2 Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccine |
| 02/15/2006 | EP1624863A1 Improvements in or relating to anti-aromatase composition |
| 02/15/2006 | EP1624850A2 Compositions and methods for treatment of severe acute respiratory syndrome (sars) |
| 02/15/2006 | EP1624846A2 Inhibition of drug binding to serum albumin |
| 02/15/2006 | EP1624786A2 Methods for the treatment and prevention of diseases of biological conduits |
| 02/15/2006 | EP1481057B1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 02/15/2006 | EP1456359B1 Preparation of vaccines using photosensitizer and light |
| 02/15/2006 | EP1003550B1 Receptor specific transepithelial transport of therapeutics |
| 02/15/2006 | EP0871738B1 Viral recombinant pseudo-particles and vaccinal and anti-tumoral applications |
| 02/15/2006 | EP0840794B1 Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells |
| 02/15/2006 | EP0791050B1 Vectors for tissue-specific replication |
| 02/15/2006 | EP0762892B1 Diphtheria toxin vaccines bearing a mutated r domain |
| 02/15/2006 | CN1735689A Bacterial virulence genes |
| 02/15/2006 | CN1735684A P153 and P156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof |
| 02/15/2006 | CN1735630A Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| 02/15/2006 | CN1735629A Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |